VTYX

Ventyx Biosciences, Inc. (NASDAQ:VTYX) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Encinitas, California. The company went public in October 2021 and focuses on developing small molecule therapies for inflammatory diseases and autoimmune disorders. Ventyx operates as a pure-play biotechnology company with no current revenue, dedicating its resources entirely to advancing multiple drug candidates through clinical trials targeting conditions such as psoriasis, inflammatory bowel disease, and neuroinflammatory disorders.